申请人:Merck & Co., Inc.
公开号:US04957912A1
公开(公告)日:1990-09-18
Novel antibiotics of the formula: ##STR1## and its salts, esters and amides wherein R is acyl; B is H, OMe, Me or SR wherein R is lower alkyl or aryl; A.sup.1 is hydrogen, hydroxy, or an organic group; and, X is a divalent radical selected from --O--, --CH.sub.2 --, or --NY-- where Y is hydrogen or lower alkyl of from 1 to 6 carbon atoms such as methyl, ethyl, i-propyl, n-butyl, n-pentyl, n-hexyl and the like, formyl or benzyl. This invention is directed to novel antibiotics, novel intermediates useful in their preparation, and processes for preparing the novel antibiotics. The novel antibiotics are effective against gram-negative bacteria including Proteus vulgaris, E. coli and Salmonella schottmulleri, and gram-positive bacteria including Staphylococcus aureas and Bacillus subtilis and are useful in combatting bacterial infections in animals or humans in addition to various industrial applications.
以下是翻译结果:
新型抗生素的化学式为:##STR1## 及其盐类,酯类和酰胺类,其中 R 是酰基;B 是 H、OMe、Me 或 SR,其中 R 是低碳烷基或芳基;A.sup.1 是氢、羟基或有机基团;X 是二价基团,选自 --O--、--CH.sub.2-- 或 --NY--,其中 Y 是氢或由1至6个碳原子的低碳烷基,如甲基、乙基、异丙基、正丁基、正戊基、正己基等,甲酰基或苯甲基。本发明涉及新型抗生素、其制备中有用的新型中间体和制备新型抗生素的方法。新型抗生素对革兰氏阴性菌具有抗菌作用,包括普鲁士氏菌、大肠杆菌和沙门氏菌,对革兰氏阳性菌具有抗菌作用,包括金黄色葡萄球菌和枯草杆菌,除了各种工业应用之外,还可用于治疗动物或人体的细菌感染。